Head to Head Contrast: Novartis AG (NVS) versus Its Peers
Novartis AG (NYSE: NVS) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Novartis AG to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.
Volatility and Risk
Novartis AG has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Novartis AG’s competitors have a beta of 36.02, indicating that their average share price is 3,502% more volatile than the S&P 500.
Novartis AG pays an annual dividend of $2.30 per share and has a dividend yield of 2.7%. Novartis AG pays out 81.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.5% and pay out 65.6% of their earnings in the form of a dividend.
This is a breakdown of recent ratings and recommmendations for Novartis AG and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Novartis AG Competitors||863||3776||6744||178||2.54|
Novartis AG presently has a consensus price target of $84.41, suggesting a potential downside of 0.09%. As a group, “Pharmaceuticals” companies have a potential upside of 21.27%. Given Novartis AG’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Novartis AG has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Novartis AG and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Novartis AG||$48.52 billion||$6.71 billion||30.06|
|Novartis AG Competitors||$8.17 billion||$1.09 billion||128.69|
Novartis AG has higher revenue and earnings than its competitors. Novartis AG is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Novartis AG and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Novartis AG Competitors||-2,399.93%||-68.09%||-7.33%|
Institutional & Insider Ownership
10.7% of Novartis AG shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.0% of Novartis AG shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Novartis AG competitors beat Novartis AG on 9 of the 15 factors compared.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company’s range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.